Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428711 | 0.88 | GRM2 (0.51) | ERN1HPGDJAK2CNR1GRM2 | |
| SCHEMBL31428928 | 0.87 | RIPK1 (0.44) | RIPK1ERN1HPGDPKMMKNK1 | |
| SCHEMBL24977234 | 0.87 | RIPK1 (0.44) | RIPK1ERN1HPGDPKMMKNK1 | |
| SCHEMBL31428554 | 0.86 | HPGD (0.44) | RIPK1ERN1HPGDALDH1A1CYP1A2 | |
| SCHEMBL31428712 | 0.86 | GRM2 (0.49) | ERN1HPGDGRM2PKMSMN1; SMN2 | |
| SCHEMBL31428784 | 0.86 | MAPT (0.52) | RIPK1ERN1HPGDGRM2ALDH1A1 | |
| SCHEMBL31428671 | 0.85 | HPGD (0.50) | ERN1HPGDJAK2CNR1GRM2 | |
| SCHEMBL31428604 | 0.85 | CCNC (0.43) | ERN1HPGDGRM2PKMSMN1; SMN2 | |
| SCHEMBL24977240 | 0.85 | HPGD (0.45) | RIPK1ERN1HPGDGRM2SMN1; SMN2 | |
| SCHEMBL31428994 | 0.85 | ERN1 (0.41) | ERN1HPGDCNR1GRM2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | RIPK1 546/4885ERN1 1375/4885HPGD 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.